Abstract. Human diseases such as Nijmegen breakage syndrome due to mutations in the NBS1 gene result in defects in resection of double strand breaks. NBS1 functions as part of the MRN complex which functions in homologous recombination and non-homologous end joining. NBS is a rare human autosomal recessive disorder caused by hypomorphic mutations. At the cellular level, NBS is characterized by radiosensitivity, chromosomal breakage and defective cell cycle checkpoints. NBS1 null mutations result in early embryonic lethality in mice, but NBS1 hypomorphic mutants are viable. Cells from these mice are defective in S phase and G2/M checkpoints. In humans, NBS1 polymorphisms have been associated with increased risk of breast cancer. MRN expression was reduced in the majority of breast tumors, and low expression of MRN correlated with increased histologic grade and estrogen receptor negativity. While these studies have shown NBS1 to be important in clinical outcomes of patients with breast cancer, mammary tumors are rare in the NBS1 haploinsufficient mouse. To better understand the role of NBS1 in mammary tumorigenesis, we examined the NBS1+/-;MMTV-neu mouse model. Mammary tumor latency was markedly increased in NBS1+/-;neu mice compared to NBS1+/+;neu control animals. This effect was due to increased apoptosis in early NBS1+/-;neu mammary tumors. However, NBS1+/-;neu mammary tumors were highly metastatic and demonstrated clear differences in gene expression profiles compared to control tumors. We concluded that NBS1 haploinsufficiency results in increased mammary tumor latency and metastasis.
Introduction
Double strand break repair is mediated by two major repair pathways, homologous recombination (HR) or non-homologous end joining (NHEJ) (1) . In mammalian cells more than 90% of double strand breaks are repaired by NHEJ. Both pathways are defined and their impairment is associated with cell cycle arrest, cell death, genomic instability, and cancer (2) . Human diseases such as Nijmegen breakage syndrome due to mutations in the NBS1 gene result in defects in resection of double strand breaks (3) . NBS1 functions as part of the MRN complex whose functions are not restricted to HR but are also involved NHEJ (4) . NBS is a rare human autosomal recessive disorder caused by hypomorphic mutations. This disorder is characterized by growth retardation, immunodeficiency, microcephaly, and cancer predisposition. At the cellular level, NBS is characterized by radiosensitivity, chromosomal breakage, and defective cell cycle checkpoints. NBS1 null mutations in mice result in early embryonic lethality (5) , but NBS1 hypomorphic mutants are viable (6) . Cells from these mice are defective in S phase and G2/M checkpoints. Heterozygous mice with an NBS1 null mutation and homozygous animals with hypomorphic mutations are predisposed to different types of cancer. Conditional NBS1 mutant mice also have been characterized (7) . For example, neuronal inactivation of NBS1 results in chromosomal breaks, microcephaly, growth retardation, cerebellar defects, and ataxia.
NBS1 polymorphisms have been associated with increased risk of breast cancer (8) (9) (10) . MRN expression was reduced in the majority of breast tumors (11) , and low expression of MRN correlated with increased histologic grade and estrogen receptor negativity. Response to radiotherapy correlated with high expression of the MRN complex. Patients with high numbers of ionizing radiation induced NBS1 foci had aggressive breast cancer phenotypes (12, 13) . While these studies have shown NBS1 to be important in clinical outcomes of patients with breast cancer, mammary tumors are rare in the NBS1 haploinsufficient mouse. To better understand the role of NBS1 in mammary tumorigenesis, we characterized these cancers using the NBS1+/-;MMTV-neu mouse.
Materials and methods
Transgenic mouse procedures. Animal procedures were approved by the Institutional Animal Care Committee. NBS1+/-mice (6) were crossed with the mammary tumor prone MMTV-neu transgenic strain in the FVB background (The Jackson Laboratory, Bar Harbor, ME). Tumor development in 30 NBS1+/-;neu mice was compared to that in 30 NBS1+/+;neu control mice. Mice were genotyped by PCR analysis of tail DNA samples. The mammary gland chains of female mice were examined visually and by palpation twice weekly. Tumors were measured twice weekly using calipers. Mice were euthanized 4 or 8 weeks after tumor formation followed by complete necropsy. Tumor tissue was processed for histopathologic and gene expression analyses. Statistical analysis was determined by ANOVA.
Mammary gland and tumor histopathology. For whole mount analysis, mammary glands were fixed in 3:1 ethanol:acetic acid, mounted on microscope slides, and stained with carmine-alum followed by clearing in 2:1 benzyl benzoate:benzyl alcohol. Tumor tissue was fixed in formalin for 16 h at room temperature. Tissue was dehydrated in an ethanol series followed by clearing in xylene and embedding in paraffin. Five micrometer sections were cut from the blocks and placed on poly-L-lysine coated slides. Sections were deparaffinized in xylene and stained with hematoxylin and eosin for histopathologic interpretation.
Cellular proliferation and programmed cell death analysis.
Mouse mammary tumor tissue was dissociated to single cells by trypsinization, fixed with 2% formaldehyde for 20 min at 4˚C followed by permeabilization with 70% ethanol, then washed with PBS. For proliferation analysis, cells were incubated with anti-PCNA antibody followed by anti-rabbit IgG secondary antibody conjugated to fluorescein. Cells were washed extensively with PBS. For programmed cell death analysis, cells were incubated with terminal deoxynucleotidyl transferase and fluorescein conjugated dUTP at 37˚C for 30 min followed by washing in PBS. The percentage of fluorescein positive cells in each group was determined by flow cytometry.
Reverse transcription-polymerase chain reaction. RNA was extracted from mouse mammary tumors using a commercially available kit (Qiagen, Valencia, CA) and reverse transcribed using SuperScript II reverse transcriptase according to manufacturer's instructions (Invitrogen, Carlsbad, CA). cDNA was amplified using specific primers (5'-3'): Nbs1, TTCCCCCAT ACAAGTATCCAG and AACTTAAGGAGCATCTATGCAG; Malat1, CATCCCGTTCCTTGTTACTC and AGACTACAA ACATTGTGTCGTG; Cdkn2b, GCTAAATGGGAAACC TGGAGAG and ACGTTGAGTCTGTCAGAATCC; Hif1a, CAGCTCCCTTTCTGATAAGC and TCTTCAGTTTCTGT GTCATCG; Egf, TCTGTCAACCCCTGAATAAATG and TTTCACTGGGAAAGACTTCAAG; Lalba, TACCCTGTA GTGACACCACC and TAAAACCCCCATCGAGACC; Jag1, AATGCTGAACCACTTGTAGAC and GGTGAACCT GGATCACTCTG; Areg, TGAATCATTGCCAAGCCAC and TAAAAAGTGACAACTGGGCATC; Csn1s1, CTCCATCC ACCTCATGTCTC and CGCTCAGATGATGCAACTG; Tgfb2, ATGTCTTCAGCCGAGGTCTG and CCCACATC TTCTTTCTCTGCTC; Ccnb2, GTATTACACAGGCTAC ATGGAG and ACATACAGGATCTGAGAAGCG; Dsc2, ATGCTGTGCCTTGCTTTAG and AGCATTTGGTGT TCACAGAC; Csn1s2, TCTTCGTGGTTTCCCCATC and ACTTTAATGTCTTGGCGAGAG in 20 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 63 mM KCl, 0.05% Tween 20, 1 mM EGTA, 50 µM of each dNTP, and 2.5 U Taq DNA polymerase (Roche Applied Science, Indianapolis, IN). Amplification with β-actin cDNA using primers 5'-ACAGGAAGTCCCTTGCC ATC-3' and 5'-ACTGGTCTCAAGTCAGTGTACAGG-3' as the internal control was carried out by real-time PCR (iCycler, Bio-Rad) using cycle parameters 94˚C for 25 sec, 55˚C for 1 min, and 72˚C for 1 min.
Global gene expression profiling. Total RNA was extracted from microdissected tumors (n=3 for each group) using a commercially available kit (RNEasy, Qiagen). Integrity of ribosomal RNA bands was confirmed by northern gel electrophoresis. For each hybridization, total RNA (10 µg) was converted to labeled cRNA targets. The biotinylated cRNA targets were then purified, fragmented, and hybridized to GeneChip mouse genome 430 2.0 expression arrays (Affymetrix, Santa Clara, CA) to interrogate the abundance of 39,000 possible transcripts in each sample. Affymetrix GCOS software was used to generate raw gene expression scores and normalized to the relative hybridization signal from each experiment. All gene expression scores were set to a minimum value of 2 times the background determined by GCOS software in order to minimize noise associated with less robust measurements of rare transcripts. Data was analyzed by t-test with p<0.005 followed by ratio analysis (minimum 2-fold change).
Results
The histopathology of NBS1+/-;neu mammary glands was consistent with that of NBS1+/+;neu animals, exhibiting normal mammary ductal structure in young mice (Fig. 1A) . Mice from both genotypes developed hyperplastic terminal end buds which progressed to poorly differentiated adenocarcinoma (Fig. 1B) . Monomorphic sheets of poorly differentiated epithelial cells with duct formation was observed in tumors from both NBS1+/-;neu and NBS1+/+;neu mice ( Fig. 1C and D) . Lung metastasis was observed in both groups of animals (Fig. 1E) . The tumor latency in NBS1+/-;neu mice was dramatically increased (77 weeks vs. 40 weeks for NBS1+/+;neu animals; p<0.01; Fig. 2A ). However NBS1+/-;neu mammary tumors were highly metastatic (4-fold increase in percentage of mice with metastatic tumors (p<0.02; Fig. 2B ).
To understand the increased latency of NBS1+/-;neu mammary tumors, we analyzed cellular proliferation and programmed cell death. As shown in Fig. 3A , 4 week NBS1+/-;neu tumors exhibited a 7-fold increase in apoptotic cells as determined by TUNEL analysis. The percentage of apoptotic cells in eight week NBS1+/-;neu tumors was similar to that in NBS1+/+;neu mice. We also analyzed cellular proliferation in early and late stage NBS1+/-;neu and NBS1+/+;neu mammary tumors. We did not detect significant differences in the percentages of PCNA positive cells between these groups (Fig. 3B) . We concluded that increased apoptosis in NBS1+/-;neu mammary tumors resulted in increased latency.
To understand the differences in mammary tumor phenotype in NBS1+/-;neu mice, we performed global gene expression profiling. Changes in cancer gene expression are shown in Tables I-III . Primary tumors from NBS1+/-;neu and NBS1+/+;neu were more highly related to each other than to metastatic tumors. Bioinformatic analysis revealed gene expression changes in specific pathways distinguishing NBS1+/-;neu from NBS1+/+;neu primary tumors, including metastasis (Malat1, 43.6-fold; Mmp14, 10.3-fold), cell cycle (Cdkn2b, 11.4-fold), angiogenesis (Hif1a, 6.4-fold), epidermal growth factor signaling (Egf, -8.3-fold), and differentiation (Lalba, -21.7-fold; Csn1s2b, -27.2-fold; Muc10, -100.4-fold). We also compared gene expression in NBS1+/-;neu and NBS1+/+;neu metastatic tumors. These pathways included metastasis, Notch signaling (Dlk1, 462.9-fold; Jag1, 28.6-fold; Jag2, 6.2-fold), epidermal growth factor receptor signaling (Areg, 66.3-fold; Ereg, 23.5-fold; Hbegf, 9.4-fold), fibroblast growth factor signaling (Fgfr2, 68.9-fold; Fgf1, 14.9-fold; Fgfr3, 10.9-fold), peroxisome proliferator activated receptor signaling (Pparg, 21.8-fold; Ppara, 10.1-fold, Ppargc1b, 7.1-fold), forkhead signaling (Foxa2, 42.6-fold; Foxa1, 33.6-fold; Foxp2, 19-fold; Foxq1, 18.1-fold), and differentiation (Wap, -22.1-fold; Csn3, -32.3-fold; Lalba, -212.2-fold; Csn, -310.8-fold; Csn1s1, -365.2-fold). Finally we compared gene expression in primary and metastatic NBS1+/-;neu mammary tumors. These pathways included Notch signaling (Dlk1, 308.8-fold; Jag1, 13.9-fold; Jag2, 6.2-fold), transforming growth factor/ , and differentiation (Csn1s2a, -127.4-fold; Csn -160.8-fold; Csn3, -958.5-fold). Expression of representative genes involved in these pathways was validated by qRT-PCR in Fig. 4 . These results demonstrated specific patterns of gene expression that correlated with primary and metastatic tumor phenotype.
Discussion
Mutations in the NBS1 gene have been associated with increased risk of breast cancer (14) (15) (16) . Persistent radiation induced NBS1 foci has been associated with chromosomal instability and increased breast cancer risk (13) . In mice, NBS1 null mutation is embryonic lethal but heterozygosity renders mice susceptible to tumor formation (5). However, mammary tumors are uncommon in mouse strains with reduced NBS1 function (6) . To examine the role of NBS1 in mammary tumor formation, we examined NBS1 haploinsufficiency in the mammary tumor prone MMTV-neu strain. Reduced expression of NBS1 resulted in increased apoptosis in NBS1 heterozygous mice. This increased cell death correlated with markedly increased tumor latency in NBS1 heterozygous mice. These effects were likely due to decreased DNA repair following oncogene induced cellular proliferation. Defects in cellular proliferation were noted in the cells of NBS1 deficient mice in previous studies (6) . Increased latency correlated with decreased growth factor expression and increased cyclin dependent kinase inhibitor expression. Loss of p53 has been shown to greatly increase tumorigenesis in NBS1 mutant mice, suggesting that p53 mediated DNA damage response may be responsible for apoptosis and increased tumor latency (15) . A previous study demonstrated nuclear export of NBS1 following ionizing radiation as a mechanism of downregulating the DNA damage response (16) . Previous studies have demonstrated increased chromosomal aberrations in NBS1+/-tumors (5). Loss of NBS1 has been shown to induce supernumerary centrosomes similar to those observed in BRCA1 deficient cells, leading to increased chromosomal instability (17) . These studies demonstrate that impaired NBS1 function can result in cellular proliferation defects leading to increased tumor latency. It is interesting to speculate that tumorigenic clones that escape defective cell death pathways may be more aggressive and metastatic due to chromosomal aberrations induced by diminished NBS1 function. In support this hypothesis, increased numbers of differentially expressed genes and degregulated signaling pathways in NBS1+/-;neu tumors correlated with increased metastatic disease.
